This Brief explores the use of proteomics as a tool for biomarker discovery in human reproduction and summarizes current findings and trends of proteomic studies in both male and female infertility. This simplifies this important but complex topic and equips the novice reader with sufficient background information on the use of proteomics in human reproduction. The up-to-date scenario on proteomic investigations will also appeal to researchers and post graduate students looking to keep abreast with the latest developments in reproductive research. This review summarizes current findings of contemporary proteomic studies on infertility in both males and females with various reproductive pathologies, and its use in predicting the outcome of assisted reproduction. In human reproduction, the search for biomarkers via proteomics is a fast-evolving approach that involves the analysis of proteins in the reproductive tissues and fluids, such as the male gametes, seminal plasma, ovarian and endometrial tissue, and follicular and uterine fluid. By comparing the protein profile of a healthy, fertile individual against that of an infertile individual, the differentially expressed proteins may give an indication to certain proteins that could serve as useful biomarkers that are related to infertility. As proteomic studies continue to unravel the dynamic proteome behind various infertility conditions, there is potential for the discovery of prognostic markers that could ultimately help in both natural and assisted human reproduction.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.